Literature DB >> 7704478

The immunological adjuvant and vaccine carrier properties of liposomes.

G Gregoriadis1.   

Abstract

Animal immunization studies by numerous laboratories have shown that liposomes promote humoural and cell-mediated immunity to a wide spectrum of bacterial, protozoan and viral antigens as well as tumour cell antigens, venoms and allergens. Adjuvanticity depends on liposomal structural characteristics which determine vesicle fate in vivo and, thus, the mode of antigen interaction with antigen-presenting cells. Adjuvanticity is further promoted by receptor mediated targeting of liposomes to macrophages, or the presence of other adjuvants including cytokines. The immunoadjuvant function of liposomes is supplemented by their ability to act as a carrier for co-entrapped B and T-cell epitopes, thus eliminating the need for a carrier protein. Recently, a technique has been developed for the entrapment of live or attenuated microbial vaccines into giant liposomes under conditions which retain their viability. Liposomes containing microbial vaccines (together with other soluble antigens or cytokines) could be used as carriers of vaccines in cases where there is a need to prevent interaction of vaccines with maternal antibodies or preformed antibodies to vaccine impurities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7704478     DOI: 10.3109/10611869408996809

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  6 in total

Review 1.  Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.

Authors:  R J Mumper; H C Ledebur
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

2.  Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.

Authors:  Eleni Maria Varypataki; Koen van der Maaden; Joke Bouwstra; Ferry Ossendorp; Wim Jiskoot
Journal:  AAPS J       Date:  2014-11-12       Impact factor: 4.009

3.  Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response.

Authors:  Rady J Laborde; Oraly Sanchez-Ferras; María C Luzardo; Yoelys Cruz-Leal; Audry Fernández; Circe Mesa; Liliana Oliver; Liem Canet; Liane Abreu-Butin; Catarina V Nogueira; Mayra Tejuca; Fabiola Pazos; Carlos Álvarez; María E Alonso; Ieda M Longo-Maugéri; Michael N Starnbach; Darren E Higgins; Luis E Fernández; María E Lanio
Journal:  J Immunol       Date:  2017-03-03       Impact factor: 5.422

4.  Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.

Authors:  L Krishnan; C J Dicaire; G B Patel; G D Sprott
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

5.  Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.

Authors:  Anita Milicic; Randip Kaur; Arturo Reyes-Sandoval; Choon-Kit Tang; Jared Honeycutt; Yvonne Perrie; Adrian V S Hill
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

Review 6.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.